C$4.82
-0.82%Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
From the notes to the annual report for fiscal 2025, ending December.
Fundamentals: trailing twelve months to Sep 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
A reverse discounted-cash-flow model: the yearly growth in free cash flow over the next ten years that today's enterprise value pays for.
The price assumes less growth than the company has lately delivered.
The same assumptions for every company, so the figure compares expectations rather than valuing any one: a 9% discount rate, then 2.5% growth for ever after year 10, from the latest trailing free cash flow. Not shown for banks and insurers, or without positive free cash flow.
The companies closest in size in Drug Manufacturers - Specialty & Generic (filled from its sector when there are few), with the median and rank across all 103 in the industry.